Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921393 | 1.00 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29889405 | 1.00 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL14868820 | 1.00 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL166955 | 1.00 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3972091 | 0.98 | SLC18A3 (0.41) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Pyridine SCHEMBL28612805 | 0.93 | HTR1A (0.44) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL11492677 | 0.89 | CHEK1 (0.46) | HPGDS | |
| SCHEMBL171370 | 0.89 | CHEK1 (0.46) | HPGDS | |
| Acetic Acid SCHEMBL28811724 | 0.89 | JAK3 (0.45) | — | |
| SCHEMBL169353 | 0.89 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3315492-A1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | SLC18A3 3474/4885SIGMAR1 2843/4885HTR1A 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.